GRI
GRI Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.94
+28.38%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +26.1%
- EBIT
- +26.2%
- EPS
- +97.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +60.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -45.5%
- EBIT
- -45.4%
- Net income
- -45.7%
- EPS
- —
- Free cash flow
- -18.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026